Articles

• 

  ResearchMetabolism

  GLP-1 Beyond Weight: Sleep Apnea, Kidneys, Liver and Heart Failure — What the Trials Measured

  Tirzepatide has a sleep-apnea indication; semaglutide 1 mg has a kidney one; semaglutide 2.4 mg has an accelerated liver approval on a biopsy endpoint. Which drug, which dose, which population, which endpoint — and where the evidence stops.

  6 October 2026·10 min read
• 

  ResearchMetabolism

  The Obesity Pill Arrived: What the Trials Measured

  An oral GLP-1 was approved in April 2026, and a much-discussed amylin combination missed its head-to-head endpoint. Here is what each trial measured, in whom and for how long — and which figures come from a paper rather than a company release.

  6 October 2026·10 min read
• 

  ResearchMetabolism

  Retatrutide: what the phase 2 and phase 3 trials have shown so far, and what is still missing

  Retatrutide, a once-weekly drug acting on three hormone receptors, now has published phase 3 trials in obesity and type 2 diabetes. Here is how much weight participants lost, in whom, with which side effects, and what the trials have not yet measured.

  6 October 2026·8 min read

Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.